Edesa Biotech reported a net loss of $5.4 million for the third quarter of 2026, widening significantly from the prior year as the company ramped up clinical preparations. Despite the widening loss, management confirmed that preparations for the Phase 2 vitiligo study of EB06 are complete, with investigational site activation already underway following the quarter-end.
Key Highlights
- Research and development expenses surged to $4.0 million from $0.9 million in the prior year, primarily due to manufacturing and preparatory activities for the EB06 vitiligo trial.
- The net loss of $0.60 per share missed the consensus analyst estimate of a $0.44 loss, reflecting a 62% increase in general and administrative costs related to share-based compensation.
- Cash and cash equivalents totaled $10.3 million as of June 30, 2026, providing liquidity for the transition from preparatory work to active clinical trial execution.